Alzheimer’s Drugs Market Size and Share Outlook to 2026 - Top Leading Players Pfizer, Novartis, Eisai Co. Ltd., Lundbeck A/S, Teva Pharmaceuticals, Janssen Pharmaceutical

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.

For In depth Information Get FREE Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/1373

Key companies covered as a part of this study include:
-Pfizer, Inc.
-Janssen Pharmaceutical
-Novartis International AG
-Eisai Co. Ltd.
-Lundbeck A/S
-Teva Pharmaceuticals Industries Ltd.

Market Dynamics

Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2017, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2017, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.

Key features of the study:

This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

For More Details On this Report: https://www.coherentmarketinsights.com/market-insight/alzheimers-drugs-market-1373

It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global Alzheimer’s drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Alzheimer’s drugs market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.